Publications by authors named "Bhatu Patil"

Claim this Profile
R
Repurposing clonixin and flunixin as anti-fibrotic candidates: Computational and preclinical evaluation in bleomycin-induced pulmonary fibrosis in rats.
Chandrakant Gawli, Swapnil Gavhane, Biswajit Das, Gayatri Marathe, Sushree Subhadra Acharya, Bhatu Patil, Vishal S Patil, Chandragouda R Patil

Res Vet Sci· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Green analytical method development and validation for Flavokawain A using RP-HPLC in bulk and in-house tablet dosage forms.
Vaishnavi Pawar, Vaibhav Kadam, Bhatu Patil, Chandrakant Gawli, Iqrar Ahamad

Ann Pharm Fr· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Flavokawain A: A Natural MAO-A Inhibitor With Therapeutic Promise for Depression.
Vaishnavi Pawa, Amit Shimpi, Jong Min Oh, Vaibhav Kadam, Bhatu Patil

Chem Biodivers· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quinazoline-based fourth-generation EGFR tyrosine kinase inhibitors to overcome C797S-mediated resistance in non-small cell lung Cancer (NSCLC).
Bhatu R Patil, Kisan Pawara, Matin Shaikh, Faizan Ahmed, Chandragouda R Patil

Bioorg Chem· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lazertinib: A Cardio-Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double-Mutant Tyrosine Kinase Resistant Non-Small Cell Lung Cancer.
Chandrakant S Gawli, Narendra R Nagpure, Bhatu R Patil, Nobuaki Ochi, Nagio Takigawa

Drug Dev Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of osimertinib-induced cardiotoxicity in non-small cell lung cancer patients: a systematic review and meta-analysis.
Chandrakant S Gawli, Bhatu R Patil, Narendra R Nagpure, Chandrgaouda R Patil, Anoop Kumar

Lung Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Computational Approach for Designing Potent EGFR-TK Inhibitors: QSAR, Docking, ADMET, and Molecular Dynamics Studies.
Shital M Patil, Kalyani Asgaonkar, Shashikant Bhandari, Aishwarya M Edake, Harun Patel, Bhatu Patil

Chem Biodivers· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Catalytic Lysine745 targeting strategy in fourth-generation EGFR tyrosine kinase inhibitors to address C797S mutation resistance.
Bhatu R Patil, Harun M Patel

Eur J Med Chem· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Linezolid: Transforming It into a Selective MAO-B Inhibitor via a Toxicity-to-Activity Optimization Approach.
Mayur S Dhangar, Iqrar Ahmad, Jong Min Oh, Bhatu R Patil, Sampath Chinnam

ACS Med Chem Lett· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mycobacterial FtsZ and inhibitors: a promising target for the anti-tubercular drug development.
Yashodeep Shinde, Asama Pathan, Sampath Chinnam, Gajanan Rathod, Bhatu Patil

Mol Divers· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFR tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC).
Bhatu R Patil, Kunal V Bhadane, Iqrar Ahmad, Yogesh J Agrawal, Amit A Shimpi

Bioorg Med Chem· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis